Vertex reports Q4 2021 product revenue $2.07B (+27% YoY); guides 2022 revenue $8.4-$8.6B

VERTEX PHARMACEUTICALS INC / MA

2021-FY EPS reported $9.01 revenue$7,574,400,000

Full-year 2021 product revenue $7.57B (+22% YoY); GAAP diluted EPS $9.01, Non-GAAP $13.02.
Q4 2021 GAAP net income $770M ($3.00 diluted EPS); Non-GAAP $866M ($3.37).
FY 2022 product revenue guidance $8.4-$8.6B; combined Non-GAAP R&D+SG&A $2.70-$2.75B.
KAFTRIO approved in EU/UK for CF children 6-11; new reimbursement agreements in Spain and Netherlands.
Pipeline: VX-147 AMKD Phase 2 POC met; VX-880 T1D Day 150 data shows insulin reduction; CTX001 enrollment complete.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.